Pomerantz LLP has launched an investigation into Securitize Corp and some of its executives for possible securities fraud or unlawful business practices. The firm is advising investors who suffered losses to contact them for potential class action participation. This move highlights concerns about corporate governance and investor protection at Securitize. The investigation is ongoing, and affected shareholders may seek legal recourse through the class action process.
Regarding the investigation into Securitize Corp by Pomerantz Law Firm, here is Pluang's Financials sector market snapshot as of Oct 21, 2026 03:11 WIB: Out of 142 priced US Financials stocks, 109 rose and 32 fell today. Notable movers include AVAT at USD 1.23 with a 1-day change of +3.36% and Pluang order activity split of 48% Sell / 52% Buy, OXLC at USD 7.29 down 3.32% with 0% Sell / 100% Buy, and CG at USD 36.93 up 3.24%. The most notable figure is the typical hold time on Pluang for CG at 113 days.
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
